Are there known drug interactions between TOPAMAX and non-AED medications?
The potential for pharmacokinetic interactions between TOPAMAX and non-AEDs is somewhat limited since TOPAMAX is not highly protein bound nor is it extensively metabolized. The most notable pharmacokinetic interactions between TOPAMAX and non-AEDs identified to date are modest decreases in exposure to the estrogen component of oral contraceptives (1 mg norethindrone plus 35 mcg ethinyl estradiol) at TOPAMAX dosages ≥ 200 mg/day.